Viatris Inc.

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
11.25 ^USD	+1.17%		-0.71%	+3.88%

Apr. 18	Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	MT
Apr. 18	UK Regulator to Consider Undertakings for Theramex-Viatris Deal	MT

Viatris Inc. Provides Revenue Guidance for the Second Half 2021

August 09, 2021 at 10:00 am EDT

Viatris Inc. provided revenue guidance for the second half 2021. The company now expects second half revenue to be slightly lower than first half.

Latest news about Viatris Inc.

Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	Apr. 18	MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	Apr. 18	MT
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	Apr. 15	MT
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	CI
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	Apr. 15	CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	Apr. 14	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
UK's Theramex sees no impact to HRT products supply after CMA probe	Apr. 05	RE
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal	Apr. 04	MT
UK watchdog says Theramex-Viatris deal raises competition concerns	Apr. 04	RE
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent	Apr. 01	RE
Viatris Launches of Ryzumvi Eye Drops to Reverse Dilation in US	Apr. 01	MT
Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States	Apr. 01	CI
Viatris Seeks M&A	Mar. 27	CI
Transcript : Viatris Inc. - Special Call	Mar. 27
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing	Mar. 25	MT
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod	Mar. 18	MT
Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc..	Mar. 11	CI
Global markets live: 3M Company, Bayer, Apple, Boeing, Nvidia...	Mar. 11
Are good times already over?	Mar. 11
Viatris Says Mapi Pharma Receives FDA Complete Response Letter on Potential Multiple Sclerosis Drug	Mar. 11	MT
US FDA declines to approve Viatris's injection for multiple sclerosis	Mar. 11	RE
Viatris Insider Sold Shares Worth $1,005,609, According to a Recent SEC Filing	Mar. 06	MT

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Companyâs ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Viatris Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.12 USD

Average target price

12.4 USD

Spread / Average Target

+11.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VIATRIS INC.	+3.88%	13.21B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

Viatris Inc.

Equities

VTRS

US92556V1061

Pharmaceuticals

Viatris Inc. Provides Revenue Guidance for the Second Half 2021

Latest news about Viatris Inc.

Chart Viatris Inc.

Company Profile

Income Statement Evolution

Ratings for Viatris Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals